Regulatory expectations for your HCP analysis: meet USP <1132.1> to enhance the quality of MS-based data
25 February 2026
Translating small-molecule development to complex generics and biosimilars
On-Demand Presentation by Dr. Joseph Glajch (JLG AP Consulting)
An Overview of Key Differences of the CMC Processes in Small-Molecule Drugs and Biotherapeutics
On-Demand Presentation by by Dr Michael Dong (MWD Consulting)
Understanding the Differences Between Small-Molecule Drugs and Biotherapeutics: An Overview
On-Demand Presentation by Dr. Michael Dong (MWD Consulting)
Synthetic-Biologics Fusion Cuisine: Innovation in Analytical Characterisation of Novel Drug Modalities
On-Demand Presentation by Dr. Bingchuan Wei, MBA (Genentech)
Capillary Electrophoresis (CE) versus quantitative Polymerase Chain Reaction (qPCR) for direct quantification of intact adenovirus particles
On-Demand Presentation by Dr. Francisca Galindo Garre (Johnson & Johnson Innovative Medicine)
Universal Study Design for Instrument Changes in Pharmaceutical Release Analytics
On-Demand Presentation by Dr. Anne Ries (Boehringer Ingelheim)
Practical Examples and Regulatory Expectations for the Validation of Biotechnological Analytical Methods – Linearity Testing, Total Error Approach
On-Demand Presentation by Dr. Pierre Lebrun (Cencora – PharmaLex)
ICH Q2 Revision 2 and Method Development and Validation Objectives (Analytical Target Profile)
On-Demand Presentation by Dr. Joachim Ermer (Ermer Quality Consulting)
Insights on specification setting challenges and opportunities
On-Demand Presentation by Dr. Simona Cianetti (GSK)
Advertisement
Advertisement
Advertisement